RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC
MADRID — First-line treatment with the RET inhibitor selpercatinib (Retevmo) achieved superior outcomes in both medullary thyroid cancer (MTC) and advanced non-small cell lung cancer (NSCLC), according to results from two phase III trials presented here. In the LIBRETTO-531 trial, selpercatinib resulted in superior progression-free survival (PFS) and treatment failure-free survival (TFFS) compared with the […]